Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: The use of routine remote follow-up of patients with chronic kidney disease (CKD) is increasing exponentially. It has been suggested that online electronic patient-reported outcome measures (ePROMs) could be used in parallel, to facilitate real-time symptom monitoring aimed at improving outcomes. We tested the feasibility of this approach in a pilot trial of ePROM symptom monitoring versus usual care in patients with advanced CKD not on dialysis.
Design: A 12-month, parallel, pilot randomised controlled trial (RCT) and qualitative substudy.
Setting And Participants: Queen Elizabeth Hospital Birmingham, UK. Adult patients with advanced CKD (estimated glomerular filtration rate ≥6 and ≤15 mL/min/1.73 m, or a projected risk of progression to kidney failure within 2 years ≥20%).
Intervention: Monthly online ePROM symptom reporting, including automated feedback of tailored self-management advice and triggered clinical notifications in the advent of severe symptoms. Real-time ePROM data were made available to the clinical team via the electronic medical record.
Outcomes: Feasibility (recruitment and retention rates, and acceptability/adherence to the ePROM intervention). Health-related quality of life, clinical data (eg, measures of kidney function, kidney failure, hospitalisation, death) and healthcare utilisation.
Results: 52 patients were randomised (31% of approached). Case report form returns were high (99.5%), as was retention (96%). Overall, 73% of expected ePROM questionnaires were received. Intervention adherence was high beyond 90 days (74%) and 180 days (65%); but dropped beyond 270 days (46%). Qualitative interviews supported proof of concept and intervention acceptability, but highlighted necessary changes aimed at enhancing overall functionality/scalability of the ePROM system.
Limitations: Small sample size.
Conclusions: This pilot trial demonstrates that patients are willing to be randomised to a trial assessing ePROM symptom monitoring. The intervention was considered acceptable; though measures to improve longer-term engagement are needed. A full-scale RCT is considered feasible.
Trial Registration Number: ISRCTN12669006 and the UK NIHR Portfolio (CPMS ID: 36497).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935185 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2021-050610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wearable bioelectronics for skin cancer management.
Biomaterials
August 2025
Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA. Electronic address:
Wearable bioelectronics have transformed modern biomedical applications by enabling seamless integration with biological tissues, providing continuous, comprehensive, and personalized healthcare. Skin cancer, particularly melanoma, poses a significant clinical challenge due to its high metastatic potential and associated mortality. Traditional diagnostic approaches face limitations in accuracy, accessibility, and reproducibility, while existing treatments are often constrained by systemic toxicity and therapeutic resistance.
View Article and Find Full Text PDFSmall Extracellular Vesicles as Biomarkers in Sarcoma Follow-Up: Protocol for a Prospective, Multicentric Pilot Study.
JMIR Res Protoc
September 2025
Department of Medical Oncology, Early Phase Unit, Georges-François Leclerc Centre, Dijon, France.
Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death.
View Article and Find Full Text PDFPredicting In-Hospital Cardiac Arrest Using Machine Learning Models: Protocol for a Scoping Review.
JMIR Res Protoc
September 2025
University of Nevada, Las Vegas, Las Vegas, NV, United States.
Background: In-hospital cardiac arrest (IHCA) remains a public health conundrum with high morbidity and mortality rates. While early identification of high-risk patients could enable preventive interventions and improve survival, evidence on the effectiveness of current prediction methods remains inconclusive. Limited research exists on patients' prearrest pathophysiological status and predictive and prognostic factors of IHCA, highlighting the need for a comprehensive synthesis of predictive methodologies.
View Article and Find Full Text PDFUnderstanding the Behavioral Determinants of First Responder App Adoption by Integrating Perspectives From the Unified Theory of Acceptance and Use of Technology and Health Belief Model: Cross-Sectional Survey.
JMIR Hum Factors
September 2025
Media Psychology Lab, Department of Communication Science, KU Leuven, Leuven, Belgium.
Background: Out-of-hospital cardiac arrests (OHCAs) are a leading cause of death worldwide, yet first responder apps can significantly improve outcomes by mobilizing citizens to perform cardiopulmonary resuscitation before professional help arrives. Despite their importance, limited research has examined the psychological and behavioral factors that influence individuals' willingness to adopt these apps.
Objective: Given that first responder app use involves elements of both technology adoption and preventive health behavior, it is essential to examine this behavior from multiple theoretical perspectives.
Purpose: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.
Methods: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers.